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g.2013.0Abstract Background: Mucopolysaccharidosis (MPS) are classiﬁed into seven clinical types based
on eleven known lysosomal enzyme deﬁciencies of glycosaminoglycan (GAG) metabolism. Respi-
ratory involvement seen in most MPS types includes recurrent respiratory infections, upper and
lower airway obstruction, tracheomalacia, restrictive lung disease, and sleep disturbances.
Aim of the study: To delineate the pattern of respiratory compromise and pulmonary function
abnormalities in MPS patients.
Methods: This is a cross section observational study conducted on 30 patients recruited from the
Neurometabolic Clinic, Children’s Hospital, Cairo University over a period of 18 months. All
patients were screened ﬁrst by the quantitative determination of GAGs in urine, and diagnosis
was conﬁrmed by unidimensional electrophoresis for GAGs in urine and/or speciﬁc enzymatic assay
in blood leucocytes. Infant pulmonary functions (IPFT) were done in twenty-two patients
(<3 years of age), while 8 cases performed impulse oscillometry (IOS) test (3–6 years of age).
Results: Ages at diagnosis ranged from 1 to 9 years with a median of 2.3 years. Male to female
ratio was 4:1. Consanguinity was observed in 53.3% whereas similar family condition was present
in 40% of cases. Lumbar kyphosis was detected in 60% of cases, while scoliosis was detected in
46.7%. Results of pulmonary functions were mainly obstructive in 20 (66.6%) cases; however, com-
bined obstructive and restrictive were detected in only 6 (20%) of cases. Data showed no association5248831.
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80 M.M. El Falaki et al.between the presence of scoliosis or the presence of organomegaly and the pattern of pulmonary
function abnormalities.
Conclusions: Evaluation and follow up of patients with MPS using pulmonary function tests are
essential to detect early involvement of respiratory system and hence start treatment for respiratory
complications early in the course of the disease.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
The mucopolysaccharidosis (MPS) are lysosomal storage dis-
orders caused by the deﬁciency of enzymes required for the
stepwise breakdown of glycosaminoglycans (GAGs), also
known as mucopolysaccharides. These conditions are differen-
tiated by their clinical features and age of presentation. MPS
are rare conditions; with an estimated total incidence of
approximately 1/20,000 live births [1].
Respiratory complications affect patients with all types of
MPS and contribute to death and disability as their disease
progresses. Respiratory abnormalities result from airway
obstruction, excessive secretions, skeletal restriction and fre-
quent infections. Progressive deposition of GAGs in the soft
tissue of the throat and trachea is thought to be responsible
for the airway obstruction and dysfunction. These problems
can lead to progressive respiratory insufﬁciency, severe sleep
apnea, and sudden death from central apnea [2].
Few studies were published about respiratory functional
assessment in MPS patients. The availability of new measure-
ment systems speciﬁcally tailored to pediatric patients now al-
lows clinicians to diagnose and follow up deterioration of lung
function, which was previously challenging in this population
[3].2. Aim of the present study
The aim of the study is to assess the pattern of respiratory
compromise and pulmonary function abnormalities in MPS
patients.
3. Subjects and methods
3.1. Study design and sampling
This cross section observational study was conducted on 30
cases diagnosed as MPS and was followed up in the Neuromet-
abolic Clinic at Children’s Hospital, Cairo University over a
period of 18 months (from March 2011 till September 2012).
This work was carried out in accordance with The Code of
Ethics of The World Medical Association (Declaration of
Helsinki) and was approved by the Faculty of Medicine, Cairo
University Ethics Committee. Informed consents were received
from the families of all participants in Arabic before being
enrolled in this study.
3.2. Methods
MPS patients were screened ﬁrst by the quantitative determi-
nation of GAGs in urine, and diagnosis was conﬁrmed by uni-
dimensional electrophoresis for GAGs in urine and/or speciﬁcenzymatic assay in blood leucocytes. Quantitative GAG anal-
ysis was performed using the dimethyl-methylene blue
(DMMB) method [4]. Cellulose acetate was used to differenti-
ate and identify different types of sulfated glycans extracted
from urine in electrophoresis using Barium acetate solution
(12%) as a buffer medium and DMMB as a colorant [5].
The resulting bands were compared with the bands of GAG
standard mix solution in every run. Speciﬁc enzymatic activi-
ties using ﬂuorescent substrates a-L-iduronidase for Hurler-
Scheie [6], iduronate-sulfatase for Hunter [7], heparin-sulfami-
dase for Sanﬁlippo type A [8] and galactose 6-sulfate sulfatase
for Morquio type A [9] were performed in the homogenates of
patients’ leucocytes and referred to the total protein content of
the sample.
All selected MPS patients were subjected to comprehensive
clinical evaluation including general, respiratory, cardiac and
neurological clinical history and examinations. Magnetic Res-
onance Imaging (MRI brain), electrocardiography (ECHO) as
well as ear nose and throat (ENT) examinations were done to
all recruited cases.
Pulmonary functions using infant lung functions (IPFT) for
infants <3 years old, while impulse oscillometry (IOS) was
used for preschool children aged 3–6 years. Infant pulmonary
functions tests were performed using Master screen Babybody
(V.4.53 Erich Jaeger GmbH, Wurzburg, Germany) [10]. Rou-
tine safety measures in pulmonary function test laboratory
were taken including full resuscitation equipment, two trained
personnel during testing, continuous monitoring using pulse
oximetry, use of transparent face mask and adherence to a spe-
ciﬁc protocol for sedation. Patients with any contraindication
to perform pulmonary functions as severe upper respiratory
obstruction were excluded from the study. Patients with his-
tory of upper respiratory tract infections were deferred for
3 weeks following attack. Length and weight were measured
on each occasion together with proper posturing to avoid ﬂex-
ion or rotation of the neck. Fasting was not indicated. Refer-
ence values for the supine position were available [11,12].
The following IPFT parameters were measured:
(1). Tidal breathing parameters were measured by a
pneumotachograph attached to a face mask, tidal
breathing was recorded in epochs of 30 s. Each epoch
contains at least 20 breaths. The mean of ﬁve trials
was reported [13].
(2). The single occlusion technique was used for measuring
passive respiratory mechanics in this study. The equip-
ment used for the occlusion techniques included a shut-
ter, ﬂowmeter, and transducers [14]. The length of the
occlusion was set at 400 ms. The occlusion was automat-
ically stopped once an adequate plateau had been
reached. The occlusion was also automatically stopped
if the infant inspires against the closed valve, and the
maximum length of the occlusion was set at 1000 ms.
Table 1 Clinical characteristics of the study group.
Characteristics Patient group (n= 30)
Dysmorphism 26 (86.67%)
Short stature 30 (100%)
Short stature associated with kyphosis 18 (60%)
Abnormal chest shape 8 (26.7%)
Abnormal chest auscultation 18 (60%)
Abnormal heart examination 8 (26.7%)
Hepatomegaly alone 4 (13.3%)
Hepatosplenomegaly(HSM) 20 (66.6%)
Corneal clouding 2 (6.67%)
Adenoid enlargement 18 (60%)
Data are expressed as number (%).
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suring airway resistance and functional residual capacity
according to the recommendations of the European
Respiratory Society/American Thoracic Society (ERS/
ATS) task force on standards for infant respiratory
function testing [15].
(4). The tidal rapid thoracoabdominal compression (RTC)
technique was used to measure the maximal ﬂow at
functional residual capacity (V0maxFRC) that can be pro-
duced by forced expiration from end-tidal inspiration.
Measurements of lung function with the RTC tech-
niques were performed according to the recommenda-
tions for infant respiratory function testing [16].
The oscillometry system (Masterscreen pediatric-IOS digi-
tal-Jaeger, Germany) was used for measuring lung functions
in preschool children 3–6 years old. IOS is a variant of the
forced oscillation technique (FOT). It is a rapid, non-invasive
technique, allowing the evaluation of total respiratory imped-
ance (Zrs) and providing values of its two components: total
respiratory resistance (Rrs) and total respiratory reactance
(Xrs).
3.3. Data management and statistical analysis
Results are expressed as median (minimum–maximum) or
number (%). Association between categorical data was per-
formed using Chi square test. SPSS computer program (ver-
sion 16 windows) was used for data analysis. P value 60.05
was considered signiﬁcant and 60.01 was considered highly
signiﬁcant.
4. Results
4.1. Descriptive data of the studied patients
Thirty cases with MPS were recruited from the Neurometabol-
ic Unit, Children’s Hospital, Cairo University. Their ages ran-
ged from 1 to 9 years with a median of 2.3 years and a
mean ± SD of 3.26 ± 2.28 years. Sex predilection was higher
for males (24 (80%)) in comparison to females (6 (20%)). Po-
sitive consanguinity was observed in 16/30 (53.3%) of selected
cases, while the presence of a similar condition in the family
was detected in 12 cases (40%).
MPS Patients were classiﬁed into subtypes using qualitative
GAG’s and speciﬁc enzymatic analysis; Hurler syndrome in 12
(40%), Hunter in 4 cases (13.3%), Sanﬁllipo in 8 (26.6%) and
Morquio in 6 cases (20%).
4.2. Clinical features
Regarding the clinical characteristics of the study group, mean
height measured was 83.7 ± 11.9 cm; where all patients had
short stature. Dysmorphic features were detected in 86.7%
of cases and included thick lips, large tongue, ﬂat nasal bridge
and abundant coarse hair texture. Abnormal shape of chest in-
cluded pectus carinatum in 4 cases and pectus excavatum in 4
cases. Abnormal chest auscultatory ﬁndings were detected in
60% of patients and included harsh vesicular breathing with
prolonged expiration ± wheezes or crepitations. Adenoid
enlargement was detected in 18 cases and 10 of them reportedsleep disturbances (obstructive sleep apnea). Abnormal cardiac
examination included mufﬂed ﬁrst heart sound in 4 cases,
accentuated second heart sound in 2 cases and audible mur-
murs in 2 cases (Table 1).
4.3. Radiological data (imaging studies)
Radiological studies including skeletal survey, MRI brain and
Echocardiography were done to all patients and are repre-
sented in Table 2. Patients with narrow foramen magnum were
all diagnosed as Morquio disease. Dysostosis multiplex in-
cluded spatulate ribs, large skull, hypoplastic epiphyses, thick-
ened diaphyses and bullet shaped metacarpals. White matter
change in MRI brain included areas of periventricular incom-
plete myelination for age and others with areas of
dysmyelination.
4.4. Pulmonary functions
Results of pulmonary functions in the study group were
mainly obstructive in 20 (66.6%) cases, however combined
obstructive and restrictive was detected in 20% of cases only
(Table 3).
The values of the infant pulmonary function test parame-
ters of the study population and the normal reference ranges
in infancy are shown in (Table 4). The median tidal breathing
ratio (tPTEF/tE) and the median maximal expiratory ﬂow of the
study population (V0maxFRC) were lower than the normal refer-
ence ranges in infancy, while the median respiratory system
resistance (Rrs) was higher than the normal reference range.
Out of a total of 22 patients who performed infant lung
function tests, 10 (45.5%) had abnormal infant lung function
parameters. Most of them had abnormal tidal breathing ratio
(tPTEF/tE) (63.6%), and total respiratory system resistance
(Rrs) (63.6%); followed by abnormality in respiratory system
compliance (Crs) (36.4%) and functional residual capacity
(FRC) (36.4%); followed by abnormality of tidal volume
(VT) (27.3%), effective airway resistance (Reff) (27.3%) and
maximal expiratory ﬂow at functional residual capacity
(V0maxFRC) (27.3%) (Table 5).
Eight patients performed impulse oscillometry. Four of
them had abnormal total respiratory resistance (Rrs5), four
had abnormal proximal respiratory resistance (Rrs20), while
all had abnormal distal capacitive reactance (Xrs5) (Table 6).
The values of Rrs5, Rrs20 and Xrs5 by IOS of the study
population are shown in (Table 7).
Table 2 Radiological studies done to the studied patients.
Test Number Percent
X-ray
Dysostosis multiplex 24 80
Kyphoscoliotic angle (Cobb’s angle) 14 46.6
MRI brain
Normal 20 66.67
Brain atrophy 2 6.67
Narrow foramen magnum 4 13.33
White matter changes 4 13.33
Echo heart
Normal 20 66.67
Chamber enlargement and valve aﬀection 6 20.00
Valve aﬀection 4 13.33
Table 3 Results of pulmonary functions of the studied group.
Number Percent
Normal pulmonary functions 4 13.33
Obstructive airway disease 20 66.67
Combined obstructive and restrictive disease 6 20.0
Table 5 Number and percentage of patients with normal and
abnormal parameters of IPFT (n= 22).
Parameters of infant pulmonary
function tests
No. of
normal (%)
No. of
abnormal (%)
Respiratory rate (RR) 12 (54.5%) 10 (45.5%)
Tidal volume (VT) 16 (72.7%) 6 (27.3%)
Tidal breathing ratio (tPTEF/tE) 8 (36.4%) 14 (63.6%)
Respiratory system compliance (Crs) 14 (63.3%) 8 (36.4%)
Respiratory system resistance (Rrs) 8 (36.4%) 14 (63.6%)
Functional residual capacity (FRCpleth) 14 (63.6%) 8 (36.4%)
Eﬀective airway resistance (Reﬀ) 16 (72.4%) 6 (27.3%)
V0maxFRC maximal expiratory ﬂow 16 (72.2%) 6 (27.3%)
Table 6 Numbers and percentages of normal and abnormal
cases according to parameters of IOS (n= 8).
Parameters of IOS No. and %
of normal cases
No. and % of
abnormal cases
Total respiratory resistance
(Rrs5)
4 (50%) 4 (50%)
Proximal respiratory resistance
(Rrs20)
4(50%) 4 (50%)
Distal capacitive reactance
(Xrs5)
0 8 (100%)
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Regarding the association between the presence of scoliosis
and type of pulmonary function abnormalities, all patients
with normal PFT did not have scoliosis however obstructive
and mixed patterns in PFT were observed in patients with
and without scoliosis. (Table 8 and Fig. 1).
No association could be demonstrated between the pres-
ence of organomegaly and pattern of PFT as 20 (66.6%) pa-
tients who did not suffer from any organomegaly had
obstructive pattern in PFT (Table 9).
5. Discussion
MPS encompasses a group of rare lysosomal storage disorders
that are associated with the accumulation of GAGs in organs
and tissues. This accumulation can lead to the progressive
development of a variety of clinical manifestations. ENT and
respiratory problems are very common in patients with MPSTable 4 Parameters of infant pulmonary function test.
Infant pulmonary function test parameter Mean ± SD Med
Respiratory rate (breaths/min) 30.7 ± 7.3 27.1
Tidal volume (VT) (ml/kg) 9 ± 1.4 9.4
Tidal breathing ratio (tPTEF/tE) (s)
a 0.26 ± 0.10 0.24
Respiratory system compliance (Crs) (ml/kpa/kg) 12.08 ± 3.86 13.1
Respiratory system resistance (Rrs) (kpa/s/L) 3.12 ± 0.77 3.20
Functional residual capacity (FRCpleth) (ml)
b 240 ± 73 241
Eﬀective airway resistance (Reﬀ) 4 ± 3 3
V0maxFRC (ml/s)
c 133 ± 45 140
a (tPTEF/tE): ratio of time to peak total expiratory ﬂow to total expirat
b (FRCpleth): plethysmography functional residual capacity.
c V0maxFRC: maximum ﬂow at functional residual capacity.and are often among the ﬁrst symptoms to appear. Typical fea-
tures of MPS include upper and lower airway obstruction and
restrictive pulmonary disease, in addition to chronic rhino-
sinusitis, chronic ear infections, recurrent upper and lower
respiratory tract infections, obstructive sleep apnea, impaired
exercise tolerance, and respiratory failure [17].
The present study included 30 patients diagnosed as MPS,
12 as Hurler, 8 as Sanﬁllipo, 6 as Morquio and 4 as Hunter dis-
ease. Their ages at diagnosis ranged from 1 to 9 years, with a
mean ± SD 3.26 ± 2.28 years. A study done by Wraith
et al. reported that the mean age of MPS patients at diagnosis
was 9 months. It is difﬁcult to reduce this age without consid-
eration of newborn screening for MPS. An earlier age at diag-
nosis is likely to lead to better results following therapy such as
bone marrow transplantation and enzyme replacement ther-
apy. Clinical features which should arouse suspicion of MPSian Range (minimum–maximum) Reference range
23.2 (21.1–44.3) 26–31
4.5 (6.1–10.6) 8.3–10.6
0.28 (0.15–0.43) 0.26
0 12.1 (6.60–18.70) 11–15
2.46 (1.60–4.06) 2–3
266 (126–392) 217–377
10 (0–10) 2.6–6.6
169 (34–203) Girls: 192–614 Boys: 179–648
ory time.
Table 7 Values of IOS parameters in the studied patients (n= 8).
IOS Parameter Value (kPa/l/s) % Predicted
Mean ± SD Range (minimum–maximum) Mean ± SD Range (minimum–maximum)
Rrs5 1.59 ± 0.41 0.86 (1.23–2.09) 141.68 ± 58.12 116.30 (81.90–98.20)
Rrs20 1.05 ± 0.04 0.07 (1.01–1.08) 137.68 ± 44.54 100.50 (75.00–175.50)
Xrs5 0.57 ± 0.42 1.00 (1.14–0.14) 133.10 ± 112.50 255.10 (40.30–295.40)
Table 8 Comparison of PFT between patients with and
without scoliosis.
PFT Scoliosis P value
No Yes
n= 16 (%) n= 14(%)
Normal IPFT (n= 4) 4 (25%) 0 (0%) 0.103
Obstructive pattern (n= 20) 10 (62.5%) 10 (71.43%)
Both obstructive and
restrictive disease (n= 6)
2 (12.5%) 4 (28.57%)
Data are expressed as number (%).
P> 0.05 = not signiﬁcant.
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Clinical vigilance is needed for early diagnosis [18].
One of the commonest clinical presentations which should
alert the physician to the possibility of MPS is recurrent and
chronic rhinitis, enlargement of the tonsils and adenoids.
Nashed et al. conducted a study on eleven MPS patients using0
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Figure 1 Type of PFT in relation to t
Table 9 Comparison of PFT between the patients according to the
PFT Organomegaly
Hepatomegaly n= 4(
Normal IPFT(n= 4) 0 (0%)
Obstructive pattern (n= 20) 4 (100%)
Both obstructive and restrictive disease (n= 6) 0 (0%)
Data are expressed as number (%).
P value 60.5 is signiﬁcant.polysomnography, results showed that seven of 11 (64%) had
evidence of OSA and 3/7 children were classiﬁed as having se-
vere OSA [19]. The present study showed that 18 patients
(60%) had adenoid enlargement; out of them, 10 had a history
suggestive of obstructive sleep apnea, however, this was not
documented by polysomnograpy.
The measurement of urinary GAG levels is a useful screen-
ing test for the MPS disorders. The current study revealed that
10 cases had normal GAGs. A positive result is very suggestive
of an MPS, but false-negative results are very common [20].
Urine testing may be falsely negative in MPS III and IV. In
MPS III, this is due to lower urinary GAG levels and smaller
heparan sulfate fragments than in the other MPS diseases. In
MPS IV, analysis of urine may be unreliable because keratan
sulfate levels decline with age in this condition [21]. Thus, en-
zyme analysis should be performed when MPS disease is
strongly suspected, even when urinary GAG excretion appears
to be normal.
Consanguinity was observed in 53.3% whereas a similar
family condition was present in 40% of our cases. Khadhiriive pattern Both obst.&rest.
No Yes
he presence or absence of scoliosis.
presence of organomegaly.
P value
%) HSM n= 20(%) No organomegaly n= 6(%)
2 (10%) 2 (33.33%) 0.178
12 (60%) 4 (66.67%)
6 (30%) 0 (0%)
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unrelated families recruited from many regions of Tunisia. A
consanguinity rate of 77.1% with ﬁrst degree cousins was de-
tected in all families except one Hurler family and one Mor-
quio A family where the consanguinity was third cousin
degree [22].
The present study showed that the most common pattern of
PFT was the obstructive pattern in 20 cases (66.7%), however
6 cases (20%) had mixed pattern (both obstructive and restric-
tive). This could be attributed to the fact that most of our pa-
tients had upper airway obstruction. Kamin et al. monitored a
17-year-old male with Hunter syndrome over the course of a 9-
month period and observed very rapid progression of respira-
tory dysfunction as the patient lost 22% of his functional lung
capacity and there was a 25% decrease in the volume of air he
could expire in 1 s i.e. the forced expiratory volume in 1 s
(FEV1). A similar rapid deterioration in lung function in other
patients was observed [3].
Similarly, 36.4% of the patients in our study had abnormal
functional residual capacity.
Leboulanger et al. reported that patients with MPS have a
signiﬁcant reduction of the minimal cross-sectional area of the
upper airways and an increase of the airways resistance, as
compared to a matched control group [23]. Recognition of
respiratory disease and early intervention improve their sur-
vival and quality of life [24].
In the current study, vertebral column affection in the form
of lumbar kyphosis was detected in 18 cases (60%), while sco-
liosis was detected in 14 cases (46.7%). In a study done by Dal-
vie et al. on seven MPS children who underwent anterior
instrumentation for correction of a thoracolumbar gibbus
not arrested by brace treatment, preoperative kyphosis ranged
from 42 to 64 (average, 52.5). The authors declared that
kyphosis was the commonest vertebral column deformity
(45.9%), while scoliosis was found in only 4.9% [25].
The clinical disorders of the thoracic cage affect the tho-
racic motion and modify the mechanical properties of the lung
and chest wall. Restriction of chest wall reduces the total lung
capacity and results in an increase in respiratory frequency and
decreased tidal volume (VT) [26]. Rodriguez et al. demon-
strated that patients with Morquio syndrome exhibited a de-
crease in Xrs5 (P< 0.05) and an increase in Rrs (P= 0.05),
independent of the frequency by impulse oscillometry [27].
Similarly 50% of MPS patients included in the current
study had an increase in Rrs5 and Rrs20, while all had a de-
crease in Xrs5, reﬂecting a reduction of elasticity or elastic re-
coil in the peripheral lung.
This study revealed that ten out of 14 patients (71.4%) with
scoliosis had obstructive airway disease, however combined
obstructive and restrictive patterns were observed in 4/14
(28.5%) cases. However no statistically signiﬁcant association
was found between the presence of scoliosis and the parame-
ters of infant lung functions (P> 0.05). Rodriguez et al. de-
clared that the metabolic defects in Morquio disease lead to
cellular accumulation of GAGs causing skeletal, respiratory
and neurologic sequelae. If the deposition is in the lung paren-
chyma, worsening of lung compliance occurs and restrictive
lung disease can be seen [27].
A systematic review on publications over past 50 years
demonstrated that scoliosis impairs growth and development
of lungs, limits chest wall movement, and results in restrictive
ventilation defect and gas exchange dysfunction [28]. Howevermost of our patients with scoliosis (n= 14) had associated
upper airway obstruction, that’s why obstructive pattern was
the most commonly observed pattern in PFT.
6. Conclusion
We concluded that evaluation and follow up of patients with
MPS using PFT is essential to detect early involvement of
respiratory system and hence start treatment for respiratory
complications early in the course of the disease, as a signiﬁcant
amount of morbidity and mortality is attributable to respira-
tory complications.
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